dc.contributor | Amaya Guio, Jairo | |
dc.contributor | Grillo Ardila, Carlos Fernando | |
dc.creator | Vargas Rodriguez, Duvan Daniel | |
dc.creator | Suarez Higuera, Erika Viviana | |
dc.date.accessioned | 2023-01-16T20:33:33Z | |
dc.date.accessioned | 2023-06-06T23:55:17Z | |
dc.date.available | 2023-01-16T20:33:33Z | |
dc.date.available | 2023-06-06T23:55:17Z | |
dc.date.created | 2023-01-16T20:33:33Z | |
dc.date.issued | 2022 | |
dc.identifier | https://repositorio.unal.edu.co/handle/unal/82953 | |
dc.identifier | Universidad Nacional de Colombia | |
dc.identifier | Repositorio Institucional Universidad Nacional de Colombia | |
dc.identifier | https://repositorio.unal.edu.co/ | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/6651622 | |
dc.description.abstract | Riesgo de NIC 2+ de acuerdo con la edad, en mujeres que asisten al
programa de tamización de la Subred Norte entre 2017 y 2021”
Introducción: Según las últimas guías de la OMS para tamización de cáncer de cérvix
se prioriza al grupo de 30 a 50 años de edad, mientras la guías nacionales incluyen a las
paciente de 25 años hasta los 50 años. El objetivo del estudio es estimar la prevalencia
de presentar lesiones NIC2+ según el grupo etario en mujeres atendidas en la unidad de
colposcopia de la Subred Norte a partir de los hallazgos de citología, colposcopia e
histología, en el periodo de 2017 a 2021.
Materiales y Métodos: Se realizo un estudio observacional de cohorte transversal con
muestreo por conveniencia, que incluyó datos de citologías y colposcopias realizadas en
el periodo de 2017 a 2021 en la Subred Norte E.S.E (84996 datos), a los que se les
aplicaron criterios de inclusión y exclusión, y eliminación de datos de seguimiento, para
49957 datos totales, que fueron tratados con Microsoft Excel, SQL Server y Visual Basic.
Se realizó un análisis descriptivo de las variables y cálculo de prevalencia de NIC 2+ por
grupos etarios.
Resultados: Tenemos una población joven entre 30 y 50 años, la mediana de la edad
fue 42 años (RIQ 28 – 53) y el 97,52% perteneciente al régimen subsidiado. El 8% de las
mujeres tuvieron citologías anormales, de las que el 57% corresponde a ASC-US. El
40% tuvieron colposcopia anormal y la mayoría corresponden a LIE-BG. Un 60% de las
biopsias tomadas fueron positivas, de las que la mayoría son NIC 1. Se estimó una
prevalencia de 1,05% de NIC 2+ para la población total. La prevalencia de NIC2+ para
menores de 25 años fue de 0,43%, de 25 a 29 años fue de 1,82%, de 30 a 49 años de
1,39% y de 50 a 65 años fue de 0,64%.
Conclusiones: La prevalencia de NIC 2+ en las mujeres que asisten al programa de
tamización de cáncer de cuello uterino en la Subred Norte entre el periodo 2017 a 2021
es mayor en el grupo 25 a 49 años y disminuye en los grupos de 18 a 24 y de 50 a 65
años. Para nuestra población es necesaria la tamización a partir de 25 años hasta los 50
años ya que tenemos alta prevalencia de NIC2 + en este grupo de edad y para nuestros
programas de tamización no se debería dejar por fuera como lo propone la última guía
de la OMS.
Palabras clave: Citología cervicovaginal; Neoplasias del cuello uterino; Colposcopia;
Virus del papiloma humano; Organización Mundial de la salud. (Texto tomado de la fuente) | |
dc.description.abstract | Risk of CIN 2+ according to age, in women who attend the screening
program of the Northern Subnet between 2017 and 2021”
Introduction: According to the latest WHO guidelines for cervical cancer screening,
priority is given to the group of women between 30 and 50 years of age, whereas the
national guidelines include patients from 25 to 50 years of age. The objective of the study
is to estimate the prevalence of presenting CIN2+ lesions according to the age group in
women treated in the colposcopy unit of the Northern Subnet based on the findings in
their cytology, colposcopy, and histology, from 2017 to 2021.
Materials and Methods: An observational cross-sectional cohort study was carried out
with convenience sampling, which included data from cytology and colposcopy performed
in the period from 2017 to 2021 in the ESE North Subnet (84,996 data), to which criteria
of inclusion and exclusion, and removal of follow-up data was applied, for a data total of
49,957, which were treated with Microsoft Excel, SQL Server, and Visual Basic. A
descriptive analysis of the variables and calculation of the prevalence of CIN 2+ by age
group was performed.
Results: We have a young population between 30 and 50 years old, the median age was
42 years (RIQ 28 - 53) and 97.52% belonged to the subsidized regime. 8% of the women
had abnormal Pap smears, of which 57% corresponded to ASC-US. 40% had abnormal
colposcopy and most correspond to LIE-BG. 60% of the biopsies taken were positive, of
which the majority were CIN 1. A prevalence of 1.05% of CIN 2+ was estimated for the
total population. The prevalence of CIN2+ for women under 25 years of age was 0.43%,
from 25 to 29 years it was 1.82%, from 30 to 49 years it was 1.39% and from 50 to 65
years it was 0.64%.
Conclusions: The prevalence of CIN 2+ in women who attend the cervical cancer
screening program in the Northern Subnet between 2017 and 2021 is higher in the
25-49 age group and decreases in the 18-24 and the 50 to 65 years age groups.
For our population, screening is necessary for ages between 25 to 50 years, since
we have a high CIN2+ prevalence in this age group, and for our screening
programs it should not be left out as proposed by the latest WHO guide.
Key words : Papanicolaou Test, Colposcopy; Uterine Cervical Neoplasms; Prevalence;
Human papillomavirus; World Health Organization. | |
dc.language | spa | |
dc.publisher | Universidad Nacional de Colombia | |
dc.publisher | Bogotá - Medicina - Especialidad en Obstetricia y Ginecología | |
dc.publisher | Facultad de Medicina | |
dc.publisher | Bogotá, Colombia | |
dc.publisher | Universidad Nacional de Colombia - Sede Bogotá | |
dc.relation | Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2020: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA
Cancer J Clin. 2020; 68: 394-424 | |
dc.relation | Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2018). Cancer of the
cervix uteri. International journal of gynaecology and obstetrics: the official organ of
the International Federation of Gynaecology and Obstetrics, 143 Suppl 2, 22–36.
https://doi.org/10.1002/ijgo.12611 | |
dc.relation | Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M.,
Rollason, T. P., & Young, L. S. (2001). Natural history of cervical human
papillomavirus infection in young women: a longitudinal cohort study. Lancet
(London, England), 357(9271), 1831–1836. https://doi.org/10.1016/S0140-
6736(00)04956-4 | |
dc.relation | Jain MA, Limaiem F. Cancer, (2022) Cervical Intraepithelial Squamous Cell Lesion.
StatPearls Publishing | |
dc.relation | Rodríguez, A. C., Schiffman, M., Herrero, R., Wacholder, S., Hildesheim, A., Castle,
P. E., Solomon, D., Burk, R., & Proyecto Epidemiológico Guanacaste Group (2008).
Rapid clearance of human papillomavirus and implications for clinical focus on
persistent infections. Journal of the National Cancer Institute, 100(7), 513–517.
https://doi.org/10.1093/jnci/djn044 | |
dc.relation | Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007).
Human papillomavirus and cervical cancer. Lancet (London, England), 370(9590),
890–907. https://doi.org/10.1016/S0140-6736(07)61416-0 | |
dc.relation | Tainio, K. et al. (2018). Clinical course of untreated cervical intraepithelial neoplasia
grade 2 under active surveillance: systematic review and meta-analysis. BMJ
(Clinical research ed.), 360, k499. https://doi.org/10.1136/bmj.k499 | |
dc.relation | WHO guideline for screening and treatment of cervical pre-cancer lesions for
cervical cancer prevention. (2021). (2nd ed.). World Health Organization | |
dc.relation | Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019
ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical
Cancer Screening Tests and Cancer Precursors. Journal of lower genital tract
disease, 24(2), 102–131. https://doi.org/10.1097/LGT.0000000000000525 | |
dc.relation | Observatorio Nacional de Cáncer- ONC. Guía de Práctica Clínica (GPC) para la
detección y manejo de lesiones precancerosas de cuello uterino. Guía completa.
Guía No44; Guías de Práctica clínica. 2014; Colombia. Guia 14:319. | |
dc.relation | Sung, H., et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer
journal for clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 | |
dc.relation | Demarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, et
al. A Study of Partial Human Papillomavirus Genotyping in Support of the 2019
ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis.
2020 Apr 1;24(2):144–7. | |
dc.relation | Koshiol, J., Lindsay, L., Pimenta, J. M., Poole, C., Jenkins, D., & Smith, J. S. (2008).
Persistent human papillomavirus infection and cervical neoplasia: a systematic
review and meta-analysis. American journal of epidemiology, 168(2), 123–137.
https://doi.org/10.1093/aje/kwn036 | |
dc.relation | Waxman, A. G., Chelmow, D., Darragh, T. M., Lawson, H., & Moscicki, A. B. (2012).
Revised terminology for cervical histopathology and its implications for
management of high-grade squamous intraepithelial lesions of the cervix.
Obstetrics and gynecology, 120(6), 1465–1471. | |
dc.relation | Sanjosé, S., Brotons, M., & Pavón, M. A. (2018). The natural history of human
papillomavirus infection. Best practice & research. Clinical obstetrics &
gynaecology, 47, 2–13. https://doi.org/10.1016/j.bpobgyn.2017.08.015 | |
dc.relation | McBride, A. A., & Warburton, A. (2017). The role of integration in oncogenic
progression of HPV-associated cancers. PLoS pathogens, 13(4), e1006211.
https://doi.org/10.1371/journal.ppat.1006211 | |
dc.relation | Welby, S., Rosillon, D., Feng, Y., & Borys, D. (2022). Progression from human
papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25
years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine
efficacy study in China between 2008 and 2016. Expert review of vaccines, 21(3),
407–413. https://doi.org/10.1080/14760584.2022.2021077 | |
dc.relation | Gravitt, P. E., & Winer, R. L. (2017). Natural History of HPV Infection across the
Lifespan: Role of Viral Latency. Viruses, 9(10), 267.https://doi.org/10.3390/v910026 | |
dc.relation | Muñoz, N., et al, & Instituto Nacional de Cancerología HPV Study Group (2009).
Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia
in a cohort of Colombian women. British journal of cancer, 100(7), 1184–1190.
https://doi.org/10.1038/sj.bjc.6604972 | |
dc.relation | Moscicki, A. B., Ma, Y., Wibbelsman, C., Darragh, T. M., Powers, A., Farhat, S., &
Shiboski, S. (2010). Rate of and risks for regression of cervical intraepithelial
neoplasia 2 in adolescents and young women. Obstetrics and gynecology, 116(6),
1373–1380. https://doi.org/10.1097/AOG.0b013e3181fe777f | |
dc.relation | Castle, P. E., Schiffman, M., Wheeler, C. M., & Solomon, D. (2009). Evidence for
frequent regression of cervical intraepithelial neoplasia-grade 2. Obstetrics and
gynecology, 113(1), 18–25. https://doi.org/10.1097/AOG.0b013e31818f5008 | |
dc.relation | Maglennon, G. A., McIntosh, P. B., & Doorbar, J. (2014). Immunosuppression
facilitates the reactivation of latent papillomavirus infections. Journal of virology,
88(1), 710–716. https://doi.org/10.1128/JVI.02589-13 | |
dc.relation | Ting, J., Rositch, A. F., Taylor, S. M., Rahangdale, L., Soeters, H. M., Sun, X., &
Smith, J. S. (2015). Worldwide incidence of cervical lesions: a systematic review.
Epidemiology and infection, 143(2), 225–241. | |
dc.relation | Beavis, A. L., Gravitt, P. E., & Rositch, A. F. (2017). Hysterectomy-corrected cervical
cancer mortality rates reveal a larger racial disparity in the United States. Cancer,
123(6), 1044–1050. https://doi.org/10.1002/cncr.30507 | |
dc.relation | Schlichte, M. J., & Guidry, J. (2015). Current Cervical Carcinoma Screening
Guidelines. Journal of clinical medicine, 4(5), 918–932. | |
dc.relation | Malone, C., Barnabas, R. V., Buist, D. S. M., Tiro, J. A., & Winer, R. L. (2020). Costeffectiveness studies of HPV self-sampling: A systematic review. Preventive
medicine, 132, 105953. https://doi.org/10.1016/j.ypmed.2019.105953 | |
dc.relation | Ogilvie, G. S., et al. (2018). Effect of Screening With Primary Cervical HPV Testing
vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months:
The HPV FOCAL Randomized Clinical Trial. JAMA, 320(1), 43–52.
https://doi.org/10.1001/jama.2018.7464 | |
dc.relation | Koliopoulos, G., et al (2017). Cytology versus HPV testing for cervical cancer
screening in the general population. The Cochrane database of systematic reviews,
8(8). https://doi.org/10.1002/14651858.CD008587.pub2 | |
dc.relation | Cheung, L. C., et al. (2020). 2019 ASCCP Risk-Based Management Consensus
Guidelines: Methods for Risk Estimation, Recommended Management, and
Validation. Journal of lower genital tract disease, 24(2), 90–101
https://doi.org/10.1097/LGT.0000000000000528 | |
dc.relation | Liverani, C. A., et al. (2020). Cervical Cancer Screening Guidelines in the
Postvaccination Era: Review of the Literature. Journal of oncology, 2020, 8887672.
https://doi.org/10.1155/2020/8887672 | |
dc.relation | Fontham, E. T. H., et al (2020). Cervical cancer screening for individuals at average
risk: 2020 guideline update from the American Cancer Society. CA: a cancer journal
for clinicians, 70(5), 321–346. https://doi.org/10.3322/caac.21628 | |
dc.relation | Abd El All HS, et al (2007). Prevalence of cervical neoplastic lesions and Human
Papilloma Virus infection in Egypt: National Cervical Cancer Screening Project.
Infectious agents and cancer, 2, 12. https://doi.org/10.1186/1750-9378-2-12. | |
dc.relation | Hav, M., et al (2016). Prevalence of Abnormal Cervical Cytology in HIVNegative
Women Participating in a Cervical Cancer Screening Program in Calmette Hospital,
Cambodia. Asian Pacific journal of cancer prevention : APJCP, 17(7), 3101–3103. | |
dc.relation | Insinga, R. P., Glass, A. G., & Rush, B. B. (2004). Diagnoses and outcomes in
cervical cancer screening: a population-based study. American journal of obstetrics
and gynecology, 191(1), 105–113. https://doi.org/10.1016/j.ajog.2004.01.043 | |
dc.relation | Rolnick, S., LaFerla, J. J., Wehrle, D., Trygstad, E., & Okagaki, T. (1996). Pap
smear screening in a health maintenance organization: 1986-1990. Preventive
medicine, 25(2), 156–161. https://doi.org/10.1006/pmed.1996.0041 | |
dc.relation | Gustavsson, I., et al (2019). Randomised study of HPV prevalence and detection of
CIN2+ in vaginal self-sampling compared to cervical specimens collected by
medical personnel. International journal of cancer, 144(1), 89–97.
https://doi.org/10.1002/ijc.31637. | |
dc.relation | Aarnio, R., Isacson, I., Sanner, K., Gustavsson, I., Gyllensten, U., & Olovsson, M.
(2021). Comparison of vaginal self-sampling and cervical sampling by medical
professionals for the detection of HPV and CIN2+: A randomized study.
International journal of cancer, 148(12), 3051–3059.
https://doi.org/10.1002/ijc.33482 | |
dc.relation | Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, del Mistro A, et al.
Efficacy of human papillomavirus testing for the detection of invasive cervical
cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet
Oncol. 2010 Mar;11(3):249–57. https://doi.org/10.1016/S1470-2045(09)70360-2 | |
dc.relation | Naucler, P., et al. (2009). Efficacy of HPV DNA testing with cytology triage and/or
repeat HPV DNA testing in primary cervical cancer screening. Journal of the
National Cancer Institute, 101(2), 88–99. https://doi.org/10.1093/jnci/djn444 | |
dc.relation | Kitchener, H. C., et al. (2009). HPV testing in combination with liquid-based cytology
in primary cervical screening (ARTISTIC): a randomised controlled trial. The Lancet.
Oncology, 10(7), 672–682. https://doi.org/10.1016/S1470-2045(09)70156-1 | |
dc.relation | Rijkaart, D. C., et al. (2012). Human papillomavirus testing for the detection of highgrade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM
randomised controlled trial. The Lancet. Oncology, 13(1), 78–88.
https://doi.org/10.1016/S1470-2045(11)70296-0. | |
dc.relation | Ogilvie, G. S., et al. (2018). Effect of Screening With Primary Cervical HPV Testing
vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months:
The HPV FOCAL Randomized Clinical Trial. JAMA, 320(1), 43–52.
https://doi.org/10.1001/jama.2018.7464. | |
dc.rights | Reconocimiento 4.0 Internacional | |
dc.rights | http://creativecommons.org/licenses/by/4.0/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | “Riesgo de NIC 2+ de acuerdo con la edad, en mujeres que asisten al programa de tamización de la Subred Norte entre 2017 y 2021” | |
dc.type | Trabajo de grado - Especialidad Médica | |